HSTO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 geg. 2024 @ 18:24):

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products...

Stats
Dzisiejszy wolumen	424.00
Średni wolumen	17 486.00
Kapitalizacja rynkowa	683 482
EPS	$0 ( 2024-04-04 )
Następna data zysków	( $0 ) 2024-06-19
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0600
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-20	Windham-bannister Susan Richards	Buy	6 835	Stock Option (right to buy)
2023-06-20	Satz Brian	Buy	6 835	Stock Option (right to buy)
2023-06-20	Kisner Daniel L	Buy	6 835	Stock Option (right to buy)
2023-06-20	Jackson Jonathan	Buy	6 835	Stock Option (right to buy)
2023-06-20	Fuhrmann Rochelle	Buy	6 835	Stock Option (right to buy)

INSIDER POWER
76.68
Last 87 transactions
Buy: 7 685 070 \| Sell: 109 431

Histogen Inc Korelacja

10 Najbardziej pozytywne korelacje
GAINL	0.89
SVOK	0.885
TDAC	0.862
RMRM	0.86
APOP	0.847
ISNS	0.832
RNAZ	0.815

10 Najbardziej negatywne korelacje
BOCH	-0.936
SHSP	-0.877
MMAC	-0.841
NETE	-0.806

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Histogen Inc Finanse

Annual	2022
Przychody:	$3.77M
Zysk brutto:	$3.77M (100.00 %)
EPS:	$-3.26

FY	2022
Przychody:	$3.77M
Zysk brutto:	$3.77M (100.00 %)
EPS:	$-3.26

FY	2021
Przychody:	$919 000
Zysk brutto:	$699 000 (76.06 %)
EPS:	$-7.80

FY	2020
Przychody:	$2.06M
Zysk brutto:	$1.09M (52.99 %)
EPS:	$-41.60

Financial Reports:

No articles found.

Histogen Inc

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.